Determinants of Targeted Cancer Therapy Use in Community Oncology Practice: A Qualitative Study using the Theoretical Domains Framework and Rummler-Brache Process Mapping

Authors:

Abstract
BackgroundPrecision medicine holds enormous potential to improve outcomes for cancer patients, offering improved rates of cancer control and quality of life. Not all patients who could benefit from targeted cancer therapy receive it, and some who may not benefit do receive targeted therapy. We sought to comprehensively identify determinants of targeted therapy use among community oncology programs, where most cancer patients receive their care.MethodsGuided by the Theoretical Domains Framework, we conducted semi-structured interviews with 24 community cancer care providers and mapped targeted therapy delivery across 11 cancer care delivery teams using a Rummler-Brache Diagram. Transcripts were coded to the framework using template analysis, and inductive coding was used to identify key behaviors. Coding was revised until consensus was reached.ResultsWe identified distinctly different processes and determinants for 1) somatic and molecular testing and 2) delivery of targeted therapies. Although motivation and intention to offer genomic testing and targeted therapies were high, professional roles and identities were challenged across targeted therapy delivery. Community oncologists’ role as generalist providers was threatened by the knowledge demands of genomic testing. Further oncologists’ role in testing was inconsistent with not only their more traditional role as treatment decision maker, but also pathologists’ role to comprehensively stage tumors. In addition, new roles were emerging or intensifying in the pathology and treatment teams to manage orders from reference laboratories and to ensure patients had access to costly therapies. Professional society guidance and greater institutional standardization were desired for testing, test reporting, and treatment protocols. Benefits for testing (preventing harms and avoiding costs) and treatment (better outcomes, but long-term use without cure) were different and may impact commitment to each behavior differentially.ConclusionsIntervention strategies that address tumor testing and treatment as distinct behaviors with unique determinants may offer promising implementation strategies to improve cancer care delivery as the processes fall to different cancer care delivery teams. Coupling process mapping with determinant analysis may improve the quality of determinant analyses and the subsequent implementation interventions proposed.Trial Registrationn/a